Korea Aims To Nurture Device Sector In Broad Grand Plan
This article was originally published in PharmAsia News
In an effort to adapt to changing global market trends amid the convergence of IT and healthcare, South Korea has released a new strategic plan to support the development of promising medical devices. The measures, which come after a similar grand strategy for the biomedicine sector, include plans to support new R&D projects, increase clinical trial support centers and designate innovative device firms.
You may also be interested in...
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
After completing a major financing last year, expectations are rising at D&D Pharmatech as it progresses large-scale, Phase II global trials with its neuroinflammation pipeline for Parkinson’s and Alzheimer’s disease. Its CEO talks to Scrip about what's in store for the South Korean biotech.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.